Illumina, Inc. $ILMN Shares Bought by Cardiff Park Advisors LLC

Cardiff Park Advisors LLC raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 258.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,137 shares of the life sciences company’s stock after buying an additional 4,424 shares during the period. Cardiff Park Advisors LLC’s holdings in Illumina were worth $756,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Capital World Investors lifted its stake in Illumina by 0.6% during the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after acquiring an additional 124,323 shares in the last quarter. State Street Corp grew its position in Illumina by 3.2% in the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock valued at $811,895,000 after acquiring an additional 190,324 shares in the last quarter. WCM Investment Management LLC increased its stake in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the period. AQR Capital Management LLC increased its stake in Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after purchasing an additional 1,028,099 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Illumina by 4.8% during the fourth quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock worth $375,260,000 after purchasing an additional 130,139 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Neutral Sentiment: Illumina was highlighted in a batch of valuation and relative-performance articles comparing it with peers such as Exelixis and Celldex Therapeutics, which may be keeping attention on whether ILMN looks cheap or expensive versus other healthcare names. EXEL vs. ILMN: Which Stock Is the Better Value Option?
• Neutral Sentiment: Analyst sentiment remained middling, with Illumina reported as having an average “Hold” recommendation, suggesting Wall Street is not seeing an immediate reason to aggressively buy or sell the shares. Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Hold” by Analysts
• Neutral Sentiment: Coverage around Illumina’s role in the Billion Cell Atlas alliance and broader genomics/CRISPR collaboration was noted in commentary on AstraZeneca, but this appears more like a long-term strategic backdrop than a near-term stock mover. AstraZeneca (LSE:AZN) And The Valuation Case Behind Its Drug Pipeline Narrative
• Neutral Sentiment: Short-interest data showed no meaningful change in reported shares outstanding for short positions, so there is no clear evidence here of a new bearish squeeze or panic selling signal.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Citigroup raised their price objective on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Canaccord Genuity Group upped their target price on shares of Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Saturday, July 18th. Barclays raised their price target on shares of Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a research report on Wednesday, June 24th. Finally, Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a research note on Thursday, May 14th. Nine analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $156.88.

Insider Activity at Illumina

In other news, SVP Christensen Jakob Wedel sold 700 shares of Illumina stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the sale, the senior vice president directly owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 1,500 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total transaction of $225,150.00. Following the transaction, the chief accounting officer owned 14,946 shares of the company’s stock, valued at approximately $2,243,394.60. The trade was a 9.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock worth $155,710,908 over the last ninety days. 2.90% of the stock is currently owned by insiders.

Illumina Stock Performance

Shares of ILMN opened at $194.09 on Monday. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $199.14. The stock has a market capitalization of $29.37 billion, a PE ratio of 35.29, a PEG ratio of 2.87 and a beta of 1.47. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The stock has a 50-day simple moving average of $171.24 and a 200-day simple moving average of $145.43.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, analysts predict that Illumina, Inc. will post 5.22 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.